Charles River Laboratories International, Inc. (CRL) Chairman James C. Foster Sells 43,154 Shares of Stock

Charles River Laboratories International, Inc. (NYSE:CRL) Chairman James C. Foster sold 43,154 shares of the company’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $100.00, for a total transaction of $4,315,400.00. Following the transaction, the chairman now owns 361,178 shares of the company’s stock, valued at $36,117,800. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Charles River Laboratories International, Inc. (NYSE CRL) traded up 0.34% during mid-day trading on Monday, reaching $100.63. The company’s stock had a trading volume of 205,509 shares. The firm has a market cap of $4.79 billion, a price-to-earnings ratio of 29.45 and a beta of 1.00. The company’s 50-day moving average is $92.20 and its 200 day moving average is $85.91. Charles River Laboratories International, Inc. has a 12 month low of $67.20 and a 12 month high of $101.20.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, May 10th. The medical research company reported $1.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.14 by $0.15. Charles River Laboratories International had a net margin of 9.28% and a return on equity of 27.46%. The business had revenue of $445.80 million during the quarter, compared to analyst estimates of $437.04 million. During the same quarter last year, the business earned $0.98 earnings per share. Charles River Laboratories International’s quarterly revenue was up 25.6% compared to the same quarter last year. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post $5.10 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Charles River Laboratories International, Inc. (CRL) Chairman James C. Foster Sells 43,154 Shares of Stock” was originally posted by sleekmoney and is the property of of sleekmoney. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://sleekmoney.com/charles-river-laboratories-international-inc-crl-chairman-james-c-foster-sells-43154-shares-of-stock/1941698.html.

Several research analysts have recently issued reports on CRL shares. Jefferies Group LLC reiterated a “buy” rating on shares of Charles River Laboratories International in a report on Thursday, March 16th. Credit Suisse Group restated a “neutral” rating and issued a $95.00 price objective (up from $89.00) on shares of Charles River Laboratories International in a report on Tuesday, June 6th. BidaskClub upgraded Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 20th. Citigroup Inc. restated a “neutral” rating and issued a $104.00 price objective (up from $90.00) on shares of Charles River Laboratories International in a report on Thursday, May 11th. Finally, Barclays PLC set a $90.00 price objective on Charles River Laboratories International and gave the company a “hold” rating in a report on Saturday, May 13th. Five equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $90.81.

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Charles River Laboratories International by 4.7% in the first quarter. Vanguard Group Inc. now owns 5,033,513 shares of the medical research company’s stock valued at $452,764,000 after buying an additional 225,563 shares during the period. BlackRock Inc. raised its stake in Charles River Laboratories International by 12,573.1% in the first quarter. BlackRock Inc. now owns 3,845,643 shares of the medical research company’s stock valued at $345,915,000 after buying an additional 3,815,298 shares during the period. FMR LLC raised its stake in Charles River Laboratories International by 39.7% in the first quarter. FMR LLC now owns 2,488,113 shares of the medical research company’s stock valued at $223,806,000 after buying an additional 707,612 shares during the period. Ariel Investments LLC raised its stake in Charles River Laboratories International by 30.7% in the first quarter. Ariel Investments LLC now owns 2,060,420 shares of the medical research company’s stock valued at $185,335,000 after buying an additional 483,564 shares during the period. Finally, State Street Corp raised its stake in Charles River Laboratories International by 1.1% in the first quarter. State Street Corp now owns 1,239,943 shares of the medical research company’s stock valued at $111,539,000 after buying an additional 13,759 shares during the period. Institutional investors and hedge funds own 98.06% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/charles-river-laboratories-international-inc-crl-chairman-james-c-foster-sells-43154-shares-of-stock/1941698.html

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *